Rajkumar Boddu, Sivacharan Kollipara, Arvind Rachapally and Tausif Ahmed*
Volume5-Issue6
Dates: Received: 2024-06-07 | Accepted: 2024-06-11 | Published: 2024-06-14
Pages: 588-596
Abstract
Modeling and simulation approaches such as Physiologically Based Pharmacokinetic (PBPK) and Physiologically Based Biopharmaceutics Modeling (PBBM) are gaining importance due to their impact to transform drug development paradigm. Development of such modeling approaches include integration of drug substance, drug product and physiological aspects followed by validation against clinical data. In this manuscript, we have highlighted utility of PBPK and PBBM in generic product development using case examples. An application where PBBM was utilized to obtain biowaivers and dissolution safe space was portrayed. Utility of such modeling approaches in obtaining fed bioequivalence studies was discussed with case example. Impact of gender evaluation on bioequivalence study outcome using PBPK approach was highlighted with a case example. Evaluation of safety aspects of extended release formulation with help of modeling approach was discussed with practical example. In the last case study, understanding the impact of critical bioavailability attributes with help of PBBM was indicated. Further, future direction in terms of sharing best practices across academia, industry and regulatory was highlighted. Overall, this manuscript summarizes experience on utilization of modeling and simulation approaches in generic product development with an aim to have more affordable and quality medicines to the patients.
FullText HTML
FullText PDF
DOI: 10.37871/jbres1931
Certificate of Publication
Copyright
© 2024 Boddu R, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Boddu R, Kollipara S, Rachapally A, Ahmed T. Experience on Utilization of Novel Modeling & Simulation Approaches in Generic Product Developmentc. J Biomed Res Environ Sci. 2024 Jun 14; 5(6): 588-596. doi: 10.37871/jbres1931, Article ID: JBRES1931, Available at: https://www.jelsciences.com/articles/jbres1931.pdf
Subject area(s)
References
- Yuvaneshwari K, Kollipara S, Ahmed T, Chachad S. Applications of PBPK/PBBM modeling in generic product development: An industry perspective. J Drug Del Sci Technol. 2022;69:103152. doi: 10.1016/j.jddst.2022.103152.
- Aishwarya R, Murthy A, Ahmed T, Chachad S. A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation. J Pharm Sci. 2022 Jun;111(6):1820-1832. doi: 10.1016/j.xphs.2022.02.007. Epub 2022 Feb 23. PMID: 35217007.
- Bhattiprolu AK, Kollipara S, Ahmed T, Boddu R, Chachad S. Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in Regulatory Perspective: Application to Supersede f2, Enabling Biowaivers & Creation of Dissolution Safe Space. J Pharm Sci. 2022 Dec;111(12):3397-3410. doi: 10.1016/j.xphs.2022.09.003. Epub 2022 Sep 9. PMID: 36096285.
- Ahmed T, Kollipara S, Boddu R, Bhattiprolu AK. Biopharmaceutics Risk Assessment-Connecting Critical Bioavailability Attributes with In Vitro, In Vivo Properties and Physiologically Based Biopharmaceutics Modeling to Enable Generic Regulatory Submissions. AAPS J. 2023 Jul 27;25(5):77. doi: 10.1208/s12248-023-00837-y. PMID: 37498474.
- Boddu R, Kollipara S, Vijaywargi G, Ahmed T. Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions. Xenobiotica. 2023 Apr;53(4):260-278. doi: 10.1080/00498254.2023.2238048. Epub 2023 Jul 25. PMID: 37471259.
- Wu D, Sanghavi M, Kollipara S, Ahmed T, Saini AK, Heimbach T. Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs. Pharm Res. 2023 Feb;40(2):337-357. doi: 10.1007/s11095-022-03319-6. Epub 2022 Jul 15. PMID: 35840856.
- Physiologically based pharmacokinetic analyses- Format and content guidance for industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2018.
- EMA Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. 2018.
- Boddu R, Kollipara S, Bhattiprolu AK, Ahmed T. Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics - a case study and utility in regulatory justifications. Xenobiotica. 2023 Oct-Nov;53(10-11):587-602. doi: 10.1080/00498254.2023.2289160. Epub 2023 Dec 19. PMID: 38062540.
- Wu F, Mousa Y, Jereb R. et al. Using Mechanistic Modeling Approaches to Support Bioequivalence Assessments for Oral Products. AAPS J. 2024;26:19. https://doi.org/10.1208/s12248-024-00886-x.
- Heimbach T, Kesisoglou F, Novakovic J, Tistaert C, Mueller-Zsigmondy M, Kollipara S, Ahmed T, Mitra A, Suarez-Sharp S. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies. J Pharm Sci. 2021 Dec;110(12):3896-3906. doi: 10.1016/j.xphs.2021.09.017. Epub 2021 Sep 20. PMID: 34551349.
- Jaiswal S, Ahmed T, Kollipara S, Bhargava M, Chachad S. Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets. Drug Dev Ind Pharm. 2021 May;47(5):778-789. doi: 10.1080/03639045.2021.1934870. Epub 2021 Jun 8. PMID: 34082622.
- Kollipara S, Martins FS, Sanghavi M, Santos GML, Saini A, Ahmed T. Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives. J Pharm Sci. 2024 Feb;113(2):345-358. doi: 10.1016/j.xphs.2023.11.030. Epub 2023 Dec 1. PMID: 38043684.
- Kollipara S, Ahmed T, Bhattiprolu AK, Chachad S. In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies. Biopharmaceutics & Drug Disposition. 2021;42. doi: 10.1002/bdd.2292.
- Kollipara S, Bhattiprolu AK, Boddu R, Ahmed T, Chachad S. Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective. AAPS PharmSciTech. 2023 Feb 9;24(2):59. doi: 10.1208/s12249-023-02521-y. PMID: 36759492.
- Karnati P, Murthy A, Gundeti M, Ahmed T. Modelling Based Approaches to Support Generic Drug Regulatory Submissions-Practical Considerations and Case Studies. AAPS J. 2023 Jun 23;25(4):63. doi: 10.1208/s12248-023-00831-4. PMID: 37353655.
- Tsakalozou E, Fang L, Bi Y, van den Heuvel M, Ahmed T, Tsang YC, Lionberger R, Rostami-Hodjegan A, Zhao L. Experience Learned and Perspectives on Using Model-Integrated Evidence in the Regulatory Context for Generic Drug Products-a Meeting Report. AAPS J. 2024 Jan 10;26(1):14. doi: 10.1208/s12248-023-00884-5. PMID: 38200397.
- Kollipara S, Boddu R, Ahmed T, Chachad S. Simplified Model-Dependent and Model-Independent Approaches for Dissolution Profile Comparison for Oral Products: Regulatory Perspective for Generic Product Development. AAPS PharmSciTech. 2022 Jan 13;23(1):53. doi: 10.1208/s12249-021-02203-7. PMID: 35028797.
- USFDA guidelines on dissolution testing of immediate release solid oral dosage forms. 1997.
- EMA guidelines on guideline on the Investigation of Bioequivalence. 2010
- USFDA guidelines on extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. 1997.
- EMA guidelines on the pharmacokinetic and clinical evaluation of modified release dosage forms. 2014.
